CAR-T (Allogeneic)
Memory NK (Allogeneic)
-- WU-CART-007 was well-tolerated in patients with R/R T-ALL/LBL, with low incidence of high-grade CRS and immune-related adverse events -- …
— First Patient Dosed in this Global, Open-Label Study to Assess the Safety and Tolerability of WU-NK-101 in AML —…
-- First clinical data presented from WU-CART-007 program; data highlight promising safety profile and preliminary anti-tumor activity in patients with…
Wugen is a clinical-stage biotechnology company
Cellular therapies originating from healthy donors
Come join our growing teams in San Diego and St. Louis